AbClon said the company is expanding its CAR-T (chimeric antigen receptor-T) pipelines targeting mesothelin and CD30. CAR T-cell therapy is a form of immunotherapy using specially altered T cells to fight cancer. 

AbClon is expanding its CAR-T cell therapy pipelines for treating the solid tumor. (AbClon)
AbClon is expanding its CAR-T cell therapy pipelines for treating the solid tumor. (AbClon)

The antibody-drug developer currently has various CAR-T cell therapy pipelines, such as AT191, a blood cancer therapy targeting disease protein CD19, and AT501, an ovarian cancer therapy targeting HER2. It also has made considerable progress in research and development related to solid tumor CAR-T by, for instance, developing Affibody targeting mesothelin. 

Mesothelin is a disease protein revealed in solid cancer cells, including pancreatic cancer. It is recognized as the main target of CAR-T cell therapy. CD30 is a disease protein mainly expressed in blood cancer such as Hodgkin’s lymphoma and is actively studied following CD19 and BCMA. 

Using its original technology, the “zCAR-T” platform, AbClon uses a switching material to change and control activation, proliferation, and target materials of CAR-T cells. With one switchable platform, the company can develop targeted material on the type of specific cancer, reducing development costs thanks to its capability of mass chemical synthesis, according to the company.

“The gene therapy market will continue to grow in 2021, and CAR-T cell therapy will lead the market,” an AbClon official said. “We are expanding our pipelines using zCAR-T technology and will solidify our position as a leading biotechnology company by securing CAR-T pipeline.”   

Copyright © KBR Unauthorized reproduction, redistribution prohibited